
Julie Parkes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5501794/publications.pdf Version: 2024-02-01



LILLE DADKES

#	Article	IF	CITATIONS
1	Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study. JMIR Research Protocols, 2022, 11, e30749.	0.5	3
2	Testing key underlying assumptions of respondent-driven sampling within a real-world network of people who inject drugs. International Journal of Social Research Methodology: Theory and Practice, 2022, 25, 91-102.	2.3	1
3	The combined effect of alcohol and body mass index on risk of chronic liver disease: A systematic review and metaâ€analysis of cohort studies. Liver International, 2021, 41, 1216-1226.	1.9	12
4	Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1788-1802.	1.4	16
5	Scoping review of mental health in prisons through the COVID-19 pandemic. BMJ Open, 2021, 11, e046547.	0.8	59
6	All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study. BMC Public Health, 2021, 21, 970.	1.2	26
7	Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs. Journal of Viral Hepatitis, 2021, 28, 1274-1283.	1.0	2
8	The testing of people with any risk factor for hepatitis C in community pharmacies is costâ€effective. Journal of Viral Hepatitis, 2020, 27, 36-44.	1.0	11
9	Prioritising Hepatitis C treatment in people with multiple injecting partners maximises prevention: A real-world network study. Journal of Infection, 2020, 80, 225-231.	1.7	8
10	Coffee Consumption and Kidney Function: A Mendelian Randomization Study. American Journal of Kidney Diseases, 2020, 75, 753-761.	2.1	56
11	Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open, 2020, 10, e040970.	0.8	6
12	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. BMC Gastroenterology, 2020, 20, 104.	0.8	5
13	Baseline characteristics and outcomes of the main perpetrator programme within the Hampshire Domestic Abuse Prevention Partnership, UK: A mixed methods study. PLoS ONE, 2019, 14, e0218408.	1.1	2
14	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterology, 2019, 19, 122.	0.8	81
15	PS-057-Redefining risk of liver disease in the general population: Analysis of the health survey for England 2016. Journal of Hepatology, 2019, 70, e35.	1.8	2
16	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 371-378.	1.8	301
17	Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. journal of applied laboratory medicine, The, 2019, 3, 815-826.	0.6	45
18	Nonâ€invasive tests for the detection of oesophageal varices in compensated cirrhosis: systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 806-818.	1.6	13

JULIE PARKES

#	Article	IF	CITATIONS
19	Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose–response meta-analysis. BMJ Open, 2017, 7, e013739.	0.8	124
20	Coffee and kidney disease. International Journal of Clinical Practice, 2017, 71, e12980.	0.8	5
21	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2017, 17, 603.	1.2	11
22	Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ: British Medical Journal, 2017, 359, j5024.	2.4	477
23	Hepatitis C bio-behavioural surveys in people who inject drugs—a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling. Harm Reduction Journal, 2017, 14, 44.	1.3	8
24	The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice. journal of applied laboratory medicine, The, 2017, 1, 720-728.	0.6	8
25	Coffee, caffeine and non-alcoholic fatty liver disease?. Therapeutic Advances in Gastroenterology, 2016, 9, 417-418.	1.4	11
26	Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. Journal of Hepatology, 2016, 64, 1358-1364.	1.8	67
27	Evaluation of recruitment and selection for specialty training in public health: interim results of a prospective cohort study to measure the predictive validity of the selection process. Journal of Public Health, 2016, 38, e194-e200.	1.0	9
28	Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study. BMC Family Practice, 2015, 16, 18.	2.9	20
29	Performance of serum marker panels for liver fibrosis in chronic hepatitis C. Journal of Hepatology, 2006, 44, 462-474.	1.8	217
30	Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom. BMC Public Health, 2006, 6, 3.	1.2	33